A buying checklist for hospital and health system leaders evaluating remote prenatal ultrasound, with Pulsenmore ES as a worked example.

Hospital and health system leaders deciding whether a remote prenatal ultrasound system fits their care model can compare vendors with seven questions. Pulsenmore ES, a physician-prescribed home prenatal ultrasound system with FDA De Novo marketing authorization, is the worked example, so each answer can be compared with any other vendor. The first step is to identify who acquires the images. Remote ultrasound comes in two categories, clinician-operated handheld devices and patient-operated home systems, and the questions differ for each. Each has its own evidence and workflow questions.
The AMA vendor evaluation variables
The American Medical Association’s (AMA) Digital Health Implementation Playbook lists six vendor evaluation variables: return on investment, IT integration, HIPAA compliance and security, user experience, customer service and documented clinical outcomes. The seven questions below cover the same ground and add the clinical questions specific to ultrasound.
1. Does the authorized use match the use case?
Ask for the regulatory status, the indicated population and the stated limits. The FDA granted De Novo marketing authorization for Pulsenmore ES in an announcement dated November 3, 2025, for use in singleton pregnancies between 14 and 38 weeks of gestation, including fetal heart rate determination interpreted by healthcare professionals.
2. What evidence applies to the hospital’s patients?
Ask for peer-reviewed studies, the sponsor of each and the population studied. In a study of 100 women in Israel, fetal cardiac activity was detected in 95.3 percent of scans. The multicenter U.S. HOLA study, which supported the FDA authorization, evaluated 162 women at four institutions across 1,370 scans, with successful fetal cardiac activity assessment in 99.2 percent of clinician-guided and 96.5 percent of app-guided scans.
A retrospective cohort of 4,460 users and 102,707 matched non-users found no significant association with preterm delivery or adverse neonatal outcomes, and a randomized trial in women with recurrent pregnancy loss reported lower anxiety. An independent German study reported lower success rates across two mobile systems, which shows why a hospital should ask which device and mode each result covers.
3. Who reviews scans, and how does the workflow run?
Ask who reads each scan, how quickly, and what happens when a finding is abnormal. The Pulsenmore platform supports role-based workflows. An administrator can schedule appointments, a sonographer or midwife reviews scans and records findings, and a doctor gives the final sign-off. This helps free doctors’ time for patients who need to be seen face to face. Review capacity is a staffing decision for the hospital, so it belongs in the plan before launch. Sheba Medical Center’s hospital-at-home program for high-risk pregnancy shows a hospital placing home ultrasound inside a larger remote care workflow.
4. How does it connect to the electronic medical record?
Ask how scan data reaches the record. Pulsenmore supports secure access to scan data that can be referenced or documented in the EMR according to institutional policies.
5. How is patient data protected?
The Pulsenmore data management document lists ISO 27001 and ISO 27799 compliance and says pseudonymized scans are stored on Azure. Pulsenmore describes its teleconsultation platform as HIPAA compliant. A hospital should still request a business associate agreement and run its own security review.
6. What support does the vendor provide?
Ask how the program is set up, how staff are trained and who answers support questions. Pulsenmore works with each organization to understand its clinical needs, develop an appropriate care model and support implementation. Providers should also assess connectivity and smartphone compatibility. App-guided scans need no live session, but internet connectivity is still required to transmit scans for review.
7. How will success be measured?
The AMA playbook tells teams to define success early and to start with a small pilot. Proving clinical results can take six months or longer.
The seven questions at a glance
| Question | What to request | Pulsenmore ES information | To confirm with the vendor |
| 1. Authorized use | Indication and limits | FDA De Novo; 14 to 38 weeks; singleton | Fit with the patient mix |
| 2. Evidence | Studies and sponsors | Feasibility, accuracy, outcomes and patient experience studies | Studies for the hospital’s population |
| 3. Scan review | Reviewer and timing | Role-based workflow with physician sign-off | The hospital’s staffing model |
| 4. EMR integration | Technical documentation | Scan data can be documented in the EMR | The hospital’s EMR connection |
| 5. Data protection | Standards and agreements | ISO 27001, ISO 27799, GDPR | Business associate agreement |
| 6. Support | Onboarding plan | Care model and implementation support | Training, connectivity and service terms |
| 7. Success measures | Pilot design | American Medical Association (AMA) playbook advises a small pilot with defined measures | Measures and timeline agreed before contract |
Practical takeaways for decision-makers
First, write down the use case and confirm the authorized use matches it.
Second, request the studies, their sponsors and the populations.
Third, name the roles that review scans and the response to an abnormal scan.
Fourth, run a security and integration review with the hospital’s own teams.
Fifth, define success measures and a pilot before the contract. Pulsenmore’s review of three years of research and real-world use gives a wider picture of the clinical record.
Pulsenmore ES compared with Butterfly iQ3 and Philips Lumify
Butterfly iQ3 and Philips Lumify are handheld devices designed for a different care model than Pulsenmore ES. The table compares the three on the first question, who acquires the images, and the criteria that follow from it.
| Criterion | Pulsenmore ES | Butterfly iQ3 | Philips Lumify |
| Who acquires the images | Pregnant patient at home, by physician prescription | Qualified and trained healthcare professional | Healthcare professional in a clinical environment |
| Who interprets | Healthcare professionals review remotely, with physician sign-off | The professional operating the device, at the point of care | The professional operating the device, at the point of care |
| Care model | Clinician-led remote prenatal care between visits | Point-of-care imaging during a clinical encounter | Point-of-care imaging during a clinical encounter |
| Clinical scope | Fetal heart rate determination, singleton pregnancies, 14 to 38 weeks | Many body regions, including cardiac, abdominal, fetal and obstetric, and gynecological imaging | A similarly broad list of applications |
| Regulatory basis | FDA De Novo decision for prescribed home use | FDA record indicating use by qualified and trained healthcare professionals | FDA record describing use by healthcare professionals in clinical environments |
| Reported real-world use | More than 270,000 home ultrasound scans | Professional-use indications | Professional-use indications |
The sources are the FDA record for Butterfly iQ3, the FDA record for Philips Lumify and the FDA De Novo decision for Pulsenmore ES. The difference is who is authorized to operate each system and how it fits the care pathway.
FAQs
Q: What should a hospital ask first when evaluating remote ultrasound?
A: Who acquires the images. Clinician-operated handheld probes and patient-operated home systems serve different care pathways, and each has its own evidence and workflow questions.
Q: Why does review capacity belong in the plan before launch?
A: Review capacity is a staffing decision for the hospital, so it should be settled before launch, along with the response to an abnormal scan.
Q: Why run a pilot before a wider rollout?
A: Proving clinical results can take six months or longer. The American Medical Association (AMA) playbook tells teams to define success early and to start with a small pilot.
Q: Why does the device and mode behind a result matter?
A: An independent German study reported lower success rates across two mobile systems, which shows why a hospital should ask which device and mode each result covers.
Q: Does Pulsenmore ES connect to a hospital’s EMR?
A: Pulsenmore supports secure access to scan data that can be referenced or documented in the EMR according to institutional policies. The technical connection depends on the hospital’s system and should be confirmed during evaluation.
Q: How does Pulsenmore protect patient data?
A: The data management document lists ISO 27001 and ISO 27799 compliance, GDPR compliance and pseudonymized scans stored on Azure. Pulsenmore describes its teleconsultation platform as HIPAA compliant. A hospital should request a business associate agreement.
Q: Which patients is Pulsenmore ES intended for?
A: It is designed for use from week 14 through week 38 in single-fetus pregnancies. A physician prescription is required, and each device is personal and intended for one patient during one pregnancy.
Q: Is Pulsenmore ES available in the United States now?
A: Yes. Pulsenmore launched U.S. commercial operations in 2026, with initial agreements with the Center for Fetal Maternal Ultrasound in Los Angeles and TLC Perinatal Care in Maryland, followed by a partnership with Ouma Health. Once a provider is enrolled, eligible patients can purchase the device through Pulsenmore’s website with a prescription from their healthcare provider.